Aims :To compare the NAFLD fibrosis score and FIBROSIS 4 score to fibroscan, and affirm whether the scores shall be used as a screening tool for liver fibrosis, in place of fibroscan. Methodology: It was a cross-sectional study. Patients with fatty liver on ultrasonological examination with 200 sample size. After obtaining the informed consent the following details were collected socio-demographic details, history, co-morbidities, anthropometric measurements, Laboratory investigations. Results: the ROC curve analysis of fibroscan reveals the area under curve of 0.499 and based on the cut off value of 4.50Kpas the sensitivity and specificity was found to be 85.7% and 83.5% respectively. The ROC curve analysis of fibrosis-4 reveals the area u...
Non-alcoholic Fatty Liver Disease (NAFLD) is a chronic liver disease that is strongly related to ins...
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countr...
Nonalcoholic fatty liver disease (NAFLD) is prevalent in 20–25% of the general population and is ass...
Background. Nonalcoholic fatty liver disease (NAFLD) includes a spectrum of diseases associated with...
Background In nonalcoholic fatty liver disease (NAFLD), advanced fibrosis has been identified as ...
Background. Non-alcoholic fatty liver disease (NAFLD), an independent nosological entity, is charac...
Liver fibrosis is the most important prognostic factor in patients with nonalcoholic fatty liver dis...
Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver diseases worldwide, in...
Patients with nonalcoholic fatty liver disease (NAFLD) and advanced liver fibrosis are at the highes...
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of a metabolic syndrome. To d...
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countr...
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of a metabolic syndrome. To d...
Introduction and aim: The gold-standard for fibrosis diagnosis in non-alcoholic fatty liver disease ...
Patients with nonalcoholic fatty liver disease (NAFLD) and advanced liver fibrosis are at the highes...
Introduction: Various conditions of liver disease and the downsides of liver biopsy call for a non-i...
Non-alcoholic Fatty Liver Disease (NAFLD) is a chronic liver disease that is strongly related to ins...
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countr...
Nonalcoholic fatty liver disease (NAFLD) is prevalent in 20–25% of the general population and is ass...
Background. Nonalcoholic fatty liver disease (NAFLD) includes a spectrum of diseases associated with...
Background In nonalcoholic fatty liver disease (NAFLD), advanced fibrosis has been identified as ...
Background. Non-alcoholic fatty liver disease (NAFLD), an independent nosological entity, is charac...
Liver fibrosis is the most important prognostic factor in patients with nonalcoholic fatty liver dis...
Non-alcoholic fatty liver disease (NAFLD) is a growing cause of chronic liver diseases worldwide, in...
Patients with nonalcoholic fatty liver disease (NAFLD) and advanced liver fibrosis are at the highes...
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of a metabolic syndrome. To d...
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countr...
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of a metabolic syndrome. To d...
Introduction and aim: The gold-standard for fibrosis diagnosis in non-alcoholic fatty liver disease ...
Patients with nonalcoholic fatty liver disease (NAFLD) and advanced liver fibrosis are at the highes...
Introduction: Various conditions of liver disease and the downsides of liver biopsy call for a non-i...
Non-alcoholic Fatty Liver Disease (NAFLD) is a chronic liver disease that is strongly related to ins...
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Western countr...
Nonalcoholic fatty liver disease (NAFLD) is prevalent in 20–25% of the general population and is ass...